83.60
前日終値:
$84.27
開ける:
$84.01
24時間の取引高:
2.02M
Relative Volume:
0.52
時価総額:
$48.51B
収益:
$5.88B
当期純損益:
$1.34B
株価収益率:
35.59
EPS:
2.3489
ネットキャッシュフロー:
$799.60M
1週間 パフォーマンス:
+0.17%
1か月 パフォーマンス:
-3.74%
6か月 パフォーマンス:
+4.50%
1年 パフォーマンス:
+20.81%
Edwards Lifesciences Corp Stock (EW) Company Profile
名前
Edwards Lifesciences Corp
セクター
電話
(949) 250-2500
住所
ONE EDWARDS WAY, IRVINE, CA
EW を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-09 | アップグレード | TD Cowen | Hold → Buy |
| 2025-12-18 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-11-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | アップグレード | Jefferies | Hold → Buy |
| 2025-10-29 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-10-07 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-07-29 | アップグレード | BTIG Research | Neutral → Buy |
| 2025-04-24 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | アップグレード | Stifel | Hold → Buy |
| 2025-01-16 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-11 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-09-18 | ダウングレード | Jefferies | Buy → Hold |
| 2024-07-31 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-07-25 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-25 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-07-25 | ダウングレード | Truist | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-05-22 | アップグレード | Citigroup | Neutral → Buy |
| 2024-05-14 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-03-07 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-02-02 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-11-28 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-07-19 | 開始されました | Robert W. Baird | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Overweight |
| 2023-03-29 | 開始されました | UBS | Neutral |
| 2023-03-08 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | ダウングレード | Bernstein | Outperform → Underperform |
| 2023-01-30 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | ダウングレード | Stifel | Buy → Hold |
| 2022-10-28 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-10-26 | 開始されました | Mizuho | Buy |
| 2022-10-18 | 開始されました | Barclays | Overweight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-29 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | 開始されました | Truist | Buy |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-03-16 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | 再開されました | BofA Securities | Neutral |
| 2022-02-02 | アップグレード | UBS | Neutral → Buy |
| 2022-01-27 | 繰り返されました | Citigroup | Buy |
| 2022-01-27 | 繰り返されました | Evercore ISI | Outperform |
| 2022-01-27 | 繰り返されました | Raymond James | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Buy |
| 2022-01-27 | 繰り返されました | UBS | Neutral |
| 2021-12-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-12-15 | アップグレード | Citigroup | Neutral → Buy |
| 2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-12-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | 繰り返されました | Canaccord Genuity | Buy |
| 2021-07-30 | 繰り返されました | Deutsche Bank | Hold |
| 2021-07-30 | 繰り返されました | Jefferies | Buy |
| 2021-07-30 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-07-30 | 繰り返されました | Oppenheimer | Outperform |
| 2021-07-30 | 繰り返されました | Stifel | Buy |
| 2021-07-30 | 繰り返されました | UBS | Neutral |
| 2021-07-30 | 繰り返されました | Wells Fargo | Equal Weight |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Neutral |
| 2021-04-05 | アップグレード | Evercore ISI | In-line → Outperform |
| 2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-11 | 繰り返されました | Canaccord Genuity | Buy |
| 2020-09-11 | 開始されました | Wolfe Research | Underperform |
| 2020-04-28 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2020-02-13 | 開始されました | Goldman | Neutral |
| 2020-02-06 | 再開されました | BTIG Research | Neutral |
| 2020-01-10 | 開始されました | Oppenheimer | Outperform |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-10-24 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-09-23 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-24 | 繰り返されました | BofA/Merrill | Buy |
| 2019-03-18 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-01-18 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | 開始されました | Deutsche Bank | Hold |
| 2018-11-28 | 開始されました | UBS | Neutral |
| 2018-10-16 | 開始されました | Barclays | Underweight |
| 2018-10-02 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | ダウングレード | Guggenheim | Buy → Neutral |
すべてを表示
Edwards Lifesciences Corp (EW) 最新ニュース
Judge: Edwards/Jenavalve would create “total monopoly” - Global Competition Review
Sector Gamma AS Acquires 30,980 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Sells 25,276 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Profit Review: Will Edwards Lifesciences Corporation outperform its industry peersMarket Rally & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Heart Valve Deal Was Blocked Over Innovation Concerns - Law360
Edwards Lifesciences (NYSE:EW) Issues FY 2026 Earnings Guidance - MarketBeat
What to expect from Edwards Lifesciences' Q4 2025 earnings report - MSN
Universal Beteiligungs und Servicegesellschaft mbH Raises Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Allstate Corp Buys Shares of 21,090 Edwards Lifesciences Corporation $EW - MarketBeat
VIX Spike: Can GBFH sustain earnings growthJuly 2025 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
Aug Action: Is Edwards Lifesciences Corporation showing insider buyingQuarterly Investment Review & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Edwards Lifesciences (EW) Receives New Analyst Target Price from Piper Sandler | EW Stock News - GuruFocus
Stifel raises Edwards Lifesciences stock price target to $110 on TAVR growth - Investing.com Canada
Edwards Lifesciences Corp. Still Trying To Regain Footing - AOL.com
Does Edwards Lifesciences (EW) Have Strong Double-Digit Earnings Potential? - Yahoo Finance
What Is Edwards Lifesciences Corporation's (NYSE:EW) Share Price Doing? - Yahoo Finance
Edwards Lifesciences (NYSE:EW) S&P 500 Index Medical Device Presence - Kalkine Media
Edwards Lifesciences Corporation (NYSE:EW) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Edwards Lifesciences Corporation (NYSE:EW) Short Interest Update - MarketBeat
Edwards’ Heart Valve Clips Targeted by Cardiovalve Patent Suit - Bloomberg Law News
Market Review: Whats the outlook for Edwards Lifesciences Corporations sectorPortfolio Risk Summary & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Boston Scientific Acquires Penumbra In $14.5 Billion Bet To Dominate Thrombectomy - Benzinga
Edwards Lifesciences (EW) Valuation Check As Recent Share Momentum Meets Premium P/E Pricing - Yahoo Finance
Risk Report: Does Edwards Lifesciences Corporation align with a passive investing strategy2025 Top Gainers & Expert Curated Trade Ideas - baoquankhu1.vn
JPM26: Edwards Lifesciences targets 10% growth in 2026 - Yahoo Finance
Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now? - Yahoo Finance
Palmetto Grain Brokerage - Palmetto Grain Brokerage
What to Expect From Edwards Lifesciences' Q4 2025 Earnings Report - Yahoo Finance
Nordea Investment Management AB Sells 110,464 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Spire Wealth Management Decreases Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
UBS Revises Edwards Lifesciences (EW) Price Target and Maintains Neutral Rating | EW Stock News - GuruFocus
Barclays Raises Price Target for Edwards Lifesciences (EW) to $1 - GuruFocus
FTC Blocks Edwards Lifesciences’ $945M JenaValve Acquisition - ocbj.com
Edwards scraps Jenavalve buy in face of FTC objections - BioWorld MedTech
Edwards Lifesciences (EW) Faces Legal Setback in Acquisition Pla - GuruFocus
Edwards Lifesciences Corp Acquisition Blocked by FTC - TradingView — Track All Markets
Hardman Johnston Global Advisors LLC Cuts Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Drops Bid to Acquire JenaValve Technology - marketscreener.com
Oregon Public Employees Retirement Fund Increases Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards won’t acquire JenaValve after FTC blocks deal - MassDevice
Parnassus Investments LLC Takes $36.93 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Explores Personalized Blood Pressure Targets in New Study - MSN
US FTC wins ruling blocking Edwards Lifesciences' acquisition of JenaValve - Reuters
FTC wins ruling blocking Edwards Lifesciences' acquisition of JenaValve - Bitget
Insider Selling: Edwards Lifesciences (NYSE:EW) VP Sells $87,328.30 in Stock - MarketBeat
Edwards Lifesciences (EW) Updates Earnings Guidance for 2023 - GuruFocus
Edwards Lifesciences (EW) Acquisition Blocked by Court - GuruFocus
Edwards says co will not acquire Jenavalve - marketscreener.com
US court blocks heart valve deal; Edwards boosts outlook, backs therapy - Stock Titan
Court sides with FTC to put Edwards Lifesciences’ JenaValve acquisition on hold - MassDevice
Edwards Lifesciences (EW) CVP exercises options and sells 1,019 shares - Stock Titan
Edwards Lifesciences Corp (EW) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):